Serum Brain-derived Neurotrophic Factor Levels as a Biomarker of Treatment Response in Patients With Depression: Systematic Review and Meta-analysis.

BACKGROUND

Brain-derived neurotrophic factor (BDNF) plays a key role in the pathophysiology of depression and the mechanism of action of antidepressants. This study aimed to evaluate the changes of BDNF in patients with depression and how it is affected by antidepressant treatment through meta-analysis.

METHODS

Multiple databases (including PubMed, Embase and China National Knowledge Infrastructure (CNKI)) were searched for studies on BDNF levels in patients with depression published up to November 15, 2024. Meta-analyses of serum and plasma BDNF levels were performed using RevMan 5.4.1, with the effect sizes expressed as mean differences (MD) and 95% confidence intervals. Heterogeneity was assessed using I2 statistics (random-effects model if I2 ≥ 50%; fixed-effects if I2 < 50%).

RESULTS

Serum BDNF levels in patients with depression were significantly lower than those in healthy controls [MD = -1.54, 95% confidence intervals (CI) (-2.85 to -0.24), p = 0.02]. Antidepressant drug treatment for 6 weeks significantly increased serum BDNF levels [MD = 7.42, 95% CI (1.10-13.74), p = 0.02], but the effect of 4 weeks of treatment was not statistically significant. Plasma BDNF levels showed no statistically significant differences between depressed patients and healthy controls (p > 0.05). Sensitivity analysis indicated that the meta-analysis results were robust and not unduly influenced by any single study.

CONCLUSION

Serum BDNF levels serve as potential biomarkers in patients with depression, but their sensitivity to short-term antidepressant treatment is limited.